Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
11 May 2024
11 May 2024
Historique:
received:
14
11
2023
accepted:
30
04
2024
revised:
29
04
2024
medline:
12
5
2024
pubmed:
12
5
2024
entrez:
11
5
2024
Statut:
epublish
Résumé
We created valrubicin-loaded immunoliposomes (Val-ILs) using the antitumor prodrug valrubicin, a hydrophobic analog of daunorubicin. Being lipophilic, valrubicin readily incorporated Val-lLs that were loaded with specific antibodies. Val-ILs injected intravenously rapidly reached the bone marrow and spleen, indicating their potential to effectively target cancer cells in these areas. Following the transplantation of human pediatric B-cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), or acute myeloid leukemia (AML) in immunodeficient NSG mice, we generated patient-derived xenograft (PDX) models, which were treated with Val-ILs loaded with antibodies to target CD19, CD7 or CD33. Only a small amount of valrubicin incorporated into Val-ILs was needed to induce leukemia cell death in vivo, suggesting that this approach could be used to efficiently treat acute leukemia cells. We also demonstrated that Val-ILs could reduce the risk of contamination of CD34
Identifiants
pubmed: 38734740
doi: 10.1038/s41419-024-06715-5
pii: 10.1038/s41419-024-06715-5
doi:
Substances chimiques
Liposomes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
328Informations de copyright
© 2024. The Author(s).
Références
Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524–39.
pubmed: 33054110
pmcid: 7604619
doi: 10.3324/haematol.2020.247031
Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10:1926.
pubmed: 33946897
pmcid: 8124693
doi: 10.3390/jcm10091926
Qiu KY, Wang JY, Huang LB, Li CG, Xu LH, Liu RY, et al. Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): an open-label, multicentre, randomized, phase III clinical trial. Am J Hematol. 2023;98:869–80.
pubmed: 36877527
doi: 10.1002/ajh.26910
Yang W, Cai J, Shen S, Gao J, Yu J, Hu S, et al. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22:1322–32.
pubmed: 34329606
pmcid: 8416799
doi: 10.1016/S1470-2045(21)00328-4
Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020;5:288.
pubmed: 33335095
pmcid: 7746731
doi: 10.1038/s41392-020-00361-x
Daver N, Alotaibi AS, Bucklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35:1843–63.
pubmed: 33953290
pmcid: 8257483
doi: 10.1038/s41375-021-01253-x
Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.
pubmed: 33619261
pmcid: 7900255
doi: 10.1038/s41408-021-00425-3
Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:1–13.
doi: 10.1038/s41571-023-00754-1
Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141:467–80.
pubmed: 36322929
doi: 10.1182/blood.2021011994
Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16:494–507.
pubmed: 30837715
pmcid: 6650343
doi: 10.1038/s41571-019-0190-8
El Maghraby GM, Arafa MF. Liposomes for enhanced cellular uptake of anticancer agents. Curr Drug Deliv. 2020;17:861–73.
pubmed: 32640957
doi: 10.2174/1567201817666200708113131
Fobian SF, Cheng Z, Ten Hagen TLM. Smart lipid-based nanosystems for therapeutic immune induction against cancers: perspectives and outlooks. Pharmaceutics. 2021;14:26.
pubmed: 35056922
pmcid: 8779430
doi: 10.3390/pharmaceutics14010026
Khan AA, Allemailem KS, Almatroodi SA, Almatroudi A, Rahmani AH. Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. 3 Biotech. 2020;10:163.
pubmed: 32206497
pmcid: 7062946
doi: 10.1007/s13205-020-2144-3
Di J, Xie F, Xu Y. When liposomes met antibodies: drug delivery and beyond. Adv Drug Deliv Rev. 2020;154–5:151–62.
doi: 10.1016/j.addr.2020.09.003
Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS J. 2012;14:303–15.
pubmed: 22415612
pmcid: 3326155
doi: 10.1208/s12248-012-9330-0
Merino M, Zalba S, Garrido MJ. Immunoliposomes in clinical oncology: state of the art and future perspectives. J Control Release. 2018;275:162–76.
pubmed: 29448116
doi: 10.1016/j.jconrel.2018.02.015
Wang D, Sun Y, Liu Y, Meng F, Lee RJ. Clinical translation of immunoliposomes for cancer therapy: recent perspectives. Expert Opin Drug Deliv. 2018;15:893–903.
pubmed: 30169978
doi: 10.1080/17425247.2018.1517747
Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13:238–52.
pubmed: 5859039
doi: 10.1016/S0022-2836(65)80093-6
Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma. 2005;46:795–802.
pubmed: 16019523
doi: 10.1080/10428190500052438
Fassas A, Buffels R, Anagnostopoulos A, Gacos E, Vadikolia C, Haloudis P, et al. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study. Br J Haematol. 2002;116:308–15.
pubmed: 11841431
doi: 10.1046/j.1365-2141.2002.03292.x
Fassas A, Buffels R, Kaloyannidis P, Anagnostopoulos A. Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia. Br J Haematol. 2003;122:161–3.
pubmed: 12823360
doi: 10.1046/j.1365-2141.2003.04395_3.x
Silverman JA, Deitcher SR. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharm. 2013;71:555–64.
doi: 10.1007/s00280-012-2042-4
Kaplan LD, Deitcher SR, Silverman JA, Morgan G. Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy. Clin Lymphoma Myeloma Leuk. 2014;14:37–42.
pubmed: 24252360
doi: 10.1016/j.clml.2013.09.009
Shah NN, Merchant MS, Cole DE, Jayaprakash N, Bernstein D, Delbrook C, et al. Vincristine sulfate liposomes injection (VSLI, Marqibo(R)): results from a Phase I study in children, adolescents, and young adults with refractory solid tumors or leukemias. Pediatr Blood Cancer. 2016;63:997–1005.
pubmed: 26891067
pmcid: 6689398
doi: 10.1002/pbc.25937
Hei Y, Chen Y, Li Q, Mei Z, Pan J, Zhang S, et al. Multifunctional immunoliposomes enhance the immunotherapeutic effects of PD-L1 antibodies against melanoma by reprogramming immunosuppressive tumor microenvironment. Small. 2022;18:e2105118.
pubmed: 34915595
doi: 10.1002/smll.202105118
Hei Y, Teng B, Zeng Z, Zhang S, Li Q, Pan J, et al. Multifunctional immunoliposomes combining catalase and PD-L1 antibodies overcome tumor hypoxia and enhance immunotherapeutic effects against melanoma. Int J Nanomed. 2020;15:1677–91.
doi: 10.2147/IJN.S225807
Merino M, Lozano T, Casares N, Lana H, Troconiz IF, Ten Hagen TLM, et al. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. J Nanobiotechnol. 2021;19:102.
doi: 10.1186/s12951-021-00846-z
Merino M, Contreras A, Casares N, Troconiz IF, Ten Hagen TL, Berraondo P, et al. A new immune-nanoplatform for promoting adaptive antitumor immune response. Nanomedicine. 2019;17:13–25.
pubmed: 30654186
doi: 10.1016/j.nano.2018.12.016
Meissner JM, Toporkiewicz M, Czogalla A, Matusewicz L, Kuliczkowski K, Sikorski AF. Novel antisense therapeutics delivery systems: in vitro and in vivo studies of liposomes targeted with anti-CD20 antibody. J Control Release. 2015;220:515–28.
pubmed: 26585505
doi: 10.1016/j.jconrel.2015.11.015
Thumrongsiri N, Dana P, Bawab R, Tanyapanyachon P, Treetidnipa C, Saengkrit N, et al. Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma. Biomed Pharmacother. 2022;150:112979.
pubmed: 35461090
doi: 10.1016/j.biopha.2022.112979
Ono K, Sato T, Iyama S, Tatekoshi A, Hashimoto A, Kamihara Y, et al. A novel strategy inducing autophagic cell death in Burkitt’s lymphoma cells with anti-CD19-targeted liposomal rapamycin. Blood Cancer J. 2014;4:e180.
pubmed: 24510029
pmcid: 3944660
doi: 10.1038/bcj.2014.2
Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res. 2004;10:2530–7.
pubmed: 15073133
doi: 10.1158/1078-0432.CCR-03-0376
Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res. 2005;11:3567–73.
pubmed: 15867261
doi: 10.1158/1078-0432.CCR-04-2517
Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab’ fragments. Clin Cancer Res. 2004;10:1100–11.
pubmed: 14871990
doi: 10.1158/1078-0432.CCR-03-0041
Harata M, Soda Y, Tani K, Ooi J, Takizawa T, Chen M, et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood. 2004;104:1442–9.
pubmed: 15155467
doi: 10.1182/blood-2004-02-0588
Moles E, Howard CB, Huda P, Karsa M, McCalmont H, Kimpton K, et al. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia. Sci Transl Med. 2023;15:eabm1262.
pubmed: 37196067
doi: 10.1126/scitranslmed.abm1262
Mohamed SMA, Schofield P, McCalmont H, Moles E, Friedrich KH, Kavallaris M, et al. An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia. Int J Biol Macromol. 2023:127596.
Issa H, Swart LE, Rasouli M, Ashtiani M, Nakjang S, Jyotsana N, et al. Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia. Leukemia. 2023;37:820–34.
pubmed: 36823395
pmcid: 10079536
doi: 10.1038/s41375-023-01854-8
Saeed M, van Brakel M, Zalba S, Schooten E, Rens JA, Koning GA, et al. Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody. Int J Nanomed. 2016;11:955–75.
doi: 10.2147/IJN.S96123
Saeed M, Zalba S, Seynhaeve ALB, Debets R, Ten Hagen TLM. Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response. Int J Nanomed. 2019;14:2069–89.
doi: 10.2147/IJN.S190736
Werntz RP, Adamic B, Steinberg GD. Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC). World J Urol. 2019;37:2031–40.
pubmed: 30515595
doi: 10.1007/s00345-018-2592-0
Cookson MS, Chang SS, Lihou C, Li T, Harper SQ, Lang Z, et al. Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther Adv Urol. 2014;6:181–91.
pubmed: 25276228
pmcid: 4144261
doi: 10.1177/1756287214541798
Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol. 2013;31:1635–42.
pubmed: 22575238
doi: 10.1016/j.urolonc.2012.04.010
Kuznetsov DD, Alsikafi NF, O’Connor RC, Steinberg GD. Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. Expert Opin Pharmacother. 2001;2:1009–13.
pubmed: 11585003
doi: 10.1517/14656566.2.6.1009
McElree IM, Packiam VT, Steinberg RL, Mott SL, Gellhaus PT, Nepple KG, et al. Sequential intravesical valrubicin and docetaxel for the salvage treatment of non-muscle-invasive bladder cancer. J Urol. 2022;208:101097JU0000000000002848.
Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019;33:2767–78.
pubmed: 31690821
doi: 10.1038/s41375-019-0615-5
Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26:1569–75.
pubmed: 33020647
doi: 10.1038/s41591-020-1081-3
Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. 2022;29:1080–96.
pubmed: 34987176
pmcid: 9395272
doi: 10.1038/s41417-021-00418-1
Mori A, Kennel SJ, Huang L. Immunotargeting of liposomes containing lipophilic antitumor prodrugs. Pharm Res. 1993;10:507–14.
pubmed: 8483832
doi: 10.1023/A:1018933632318
Zhang Y, Li N, Suh H, Irvine DJ. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat Commun. 2018;9:6.
pubmed: 29295974
pmcid: 5750237
doi: 10.1038/s41467-017-02251-3
Pang A, Huo Y, Shen B, Zheng Y, Jiang E, Feng S, et al. Optimizing autologous hematopoietic stem cell transplantation for acute leukemia. Stem Cells Transl Med. 2021;10:S75–S84.
pubmed: 34724713
pmcid: 8560201
doi: 10.1002/sctm.21-0176
Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5:3–8.
pubmed: 28052991
pmcid: 5426480
doi: 10.1158/2326-6066.CIR-16-0297
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.
pubmed: 19197294
pmcid: 2828349
doi: 10.1038/nri2506
Zhao Y, Du J, Shen X. Targeting myeloid-derived suppressor cells in tumor immunotherapy: current, future and beyond. Front Immunol. 2023;14:1157537.
pubmed: 37006306
pmcid: 10063857
doi: 10.3389/fimmu.2023.1157537
Li Q, Lu J, Li J, Zhang B, Wu Y, Ying T. Antibody-based cancer immunotherapy by targeting regulatory T cells. Front Oncol. 2023;13:1157345.
pubmed: 37182149
pmcid: 10174253
doi: 10.3389/fonc.2023.1157345
Qianmei Y, Zehong S, Guang W, Hui L, Lian G. Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy. Immunol Res. 2021;69:398–414.
pubmed: 34302619
doi: 10.1007/s12026-021-09211-6
Li Z, Sun G, Sun G, Cheng Y, Wu L, Wang Q, et al. Various uses of PD1/PD-L1 inhibitor in oncology: opportunities and challenges. Front Oncol. 2021;11:771335.
pubmed: 34869005
pmcid: 8635629
doi: 10.3389/fonc.2021.771335
Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol. 2004;172:5450–5.
pubmed: 15100286
doi: 10.4049/jimmunol.172.9.5450
Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol. 2003;33:970–9.
pubmed: 12672063
doi: 10.1002/eji.200323382
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–95.
pubmed: 26516065
pmcid: 4670800
doi: 10.1158/2159-8290.CD-15-1020
Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504–6.
pubmed: 30275569
doi: 10.1038/s41591-018-0146-z
Ledererova A, Dostalova L, Kozlova V, Peschelova H, Ladungova A, Culen M, et al. Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. J Immunother Cancer. 2021;9:e002352.
pubmed: 34413165
pmcid: 8378389
doi: 10.1136/jitc-2021-002352
Hassan HT. Antibody-drug conjugate [ADC] treatment of leukaemia. Leuk Res. 2023;131:107078.
pubmed: 37331104
doi: 10.1016/j.leukres.2023.107078
Kegyes D, Jitaru C, Ghiaur G, Ciurea S, Hoelzer D, Tomuleasa C, et al. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia. Blood Rev. 2023;59:101042.
pubmed: 36732205
doi: 10.1016/j.blre.2023.101042
Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641–61.
pubmed: 37308581
doi: 10.1038/s41573-023-00709-2
Janthur WD, Cantoni N, Mamot C. Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci. 2012;13:16020–45.
pubmed: 23443108
pmcid: 3546676
doi: 10.3390/ijms131216020
Mshaik R, Simonet J, Georgievski A, Jamal L, Bechoua S, Ballerini P, et al. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias. Blood Cancer J. 2021;11:61.
pubmed: 33737511
pmcid: 7973815
doi: 10.1038/s41408-021-00450-2
Georgievski A, Michel A, Thomas C, Mlamla Z, Pais de Barros JP, Lemaire-Ewing S, et al. Acute lymphoblastic leukemia-derived extracellular vesicles affect quiescence of hematopoietic stem and progenitor cells. Cell Death Dis. 2022;13:337.
pubmed: 35414137
pmcid: 9005650
doi: 10.1038/s41419-022-04761-5